Hong Kong, Feb. 6, 2026 - (ACN Newswire via SeaPRwire.com) - Viva World Trade, Inc. ("VVWT" or the "Company"; OTCID:VVWT) is pleased to announce that Mr. Liu Xiaojun, on behalf of Fufeng Group ("Fufeng Group"; HK:00546), has successfully completed the full acquisition of the Company. This acquisition has fulfilled all necessary internal decision-making procedures and relevant regulatory requirements of OTC Markets. The transfer of equity and handover of control have been fully completed, and Mr. Liu Xiaojun, representing Fufeng Group, has formally become the sole controlling shareholder of the Company.Fufeng Group, established in Hong Kong in 2021, is a comprehensive multinational conglomerate focusing on four core business segments: international investment, cross-border trade, compliant crypto asset services, and global business agency. It is committed to providing integrated cross-border development solutions for enterprises through a dual-engine approach of "real industries + financial capital."Upholding the core operating philosophy of "Integrity, Professionalism, and Win-Win Cooperation," the Group has established multiple offices within China, building a diversified industrial ecosystem to precisely connect with premium global project resources and empower enterprises in achieving cross-border development and value enhancement. Notably, the Inner Mongolia Yellow Cattle Breeding Project (spanning 2,400 acres) has completed all preliminary preparations and is poised to enter large-scale operation, injecting robust growth momentum into the Group's real industry sector.Guided by the development logic of "industry empowering capital, capital driving industry," Fufeng Group has established its core strategic positioning: anchored in compliant operations, leveraging cross-border M&A and asset integration to facilitate the Nasdaq Main Board listing of its subsidiary Viva World Trade, Inc., thereby launching a new chapter in global capital operations.Future Planning and Strategic Deployment (Through Q1 2026)To accelerate the realization of the Group's overall strategic objectives, Fufeng Group has outlined clear directives for its affiliated entity Viva World Trade, Inc., planning to complete the following key strategic steps by the end of March 2026:1. Advance Crypto Asset Strategic Integration: By late February 2026, negotiate and execute a "triangular reverse merger transaction" with a leading crypto-native asset company. This aims to efficiently integrate innovative value from cutting-edge digital asset sectors, injecting fresh growth momentum into the Group.2. Introduce Professional Capital Services Partner: By late March 2026, establish deep cooperation with a professional investment institution possessing extensive market experience. This partnership will assist the company in global market expansion, enhance compliance operations to increase market visibility and capital allocation efficiency, and solidify the foundation of corporate value.3. Secure NASDAQ Listing Pathway: By the end of March 2026, the company plans to engage a professional advisory firm with expertise in U.S. stock market listings. A dedicated listing advancement team will be established to formally initiate preparations for a NASDAQ Main Board listing, laying a solid foundation for compliance filings and the transition to the main board.Viva World Trade, Inc. on OTC Markets: https://www.otcmarkets.com/stock/VVWT/profileForward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on management's current plans and expectations and are subject to various uncertainties and risks that could materially affect the company's current plans and expectations, as well as its future operating results and financial condition. For a more detailed list of risks and factors that could affect the Company's business prospects and cause actual results to differ materially from those described in forward-looking statements, please refer to the Company's reports and other filings with the U.S. Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Please contact:GEMZ CORPhyxinvest@yeah.net Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). GIC purchased 64,128,000 shares at an average price of approximately HK$12.18 per share, representing a total investment of roughly HK$781 million (approx. US$100 million). This transaction marks the official entry of one of the world's leading sovereign funds into Ascletis Pharma's shareholder base, drawing market attention to the renewed positioning of global long-term capital in China's innovative pharmaceutical sector.As one of the most representative sovereign funds globally, GIC's investment decisions highly emphasize certainty and the ability to navigate economic cycles. Its continuous increase in holdings in a single target usually means that its mid-to-long-term value judgment on the relevant assets has become clear. Unlike tactical transactions by short-term funds, GIC focuses more on whether the industrial logic is sound, whether R&D realization has time visibility, and the potential returns over the next few years.From a portfolio allocation perspective, GIC's decision to invest in Ascletis Pharma also reflects, to a certain extent, its recognition of the company's BD capabilities and pipeline structure. Ascletis Pharma's strategic layout in the innovative drug field exhibits differentiated characteristics, with a clear R&D pace. Its pipeline structure highly matches the "long-term, verifiable innovation" standards preferred by sovereign funds.As of now, GIC holds 64,128,000 shares of Ascletis Pharma, accounting for approximately 6.42% of the company's issued share capital (calculated based on 1,068,214,530 issued shares).Overall, GIC's current investment is more a strategic continuation of its presence in the Hong Kong innovative drug sector, rather than a short-term speculative behavior. As long-term capital gradually returns to fundamental pricing, core targets with genuine BD capabilities are re-entering the allocation scope of international capital. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Currently, digital transformation has become the core proposition of global industrial upgrading, and the manufacturing industry is also undergoing a disruptive transformation from being “experience-driven” to “data intelligence-driven”. In this process, the deep integration of artificial intelligence and industrial scenarios has become the key to resolving manufacturing complexity and unleashing productivity. The introduction of the Action Plan for Integrating and Empowering Industrial Internet and Artificial Intelligence by MIIT further marks the upgrade of “AI + Manufacturing” from an optional pathway to a mandatory one, giving rise to a blue ocean of value worth tens of trillions.As a deep participant and leader in the digital and intelligent transformation of the manufacturing industry, COSMOPlat IoT Technology Co., Ltd. (“COSMOPlat”) has, based on its profound understanding of massive data and complex scenarios in the industrial field, built a full-stack AI technology system that includes training and inference platform, large models, intelligent agent development and application platforms. This has not only redefined the implementation path of industrial digitalization and intelligentization, but also continuously strengthened its technical barriers in industrial practice, building a solid and difficult-to-replicate moat, and is expected to benefit deeply from the dividends of industrial digital and intelligent transformation and development. On January 30, COSMOPlat submitted a listing application to the HKEX, embarking on a new chapter of value realization.AI Restructuring Industrial Digitalization: Full-stack Architecture and Flywheel Effect Build Core BarriersIn traditional perception, the industrial internet is a platform for data connection and circulation, and its technical boundaries remain more at the levels of equipment access, data collection, and process visualization. However, through its original “space-air-ground integrated” full-stack AI technology system, COSMOPlat has deeply embedded “AI+” into its technology architecture, achieving an intelligent closed-loop across the entire chain from perception and decision-making to execution, transforming data into intelligent decision-making capabilities, completely overturning the technology logic of the traditional industrial internet, and building an inimitable technology moat.At the “space” level, COSMOPlat utilizes “COSMOMind”, the first domestic vertical large model based on an industrial internet platform, as its decision-making hub. “COSMOMind” deeply integrates Haier Group's over 40 years of manufacturing knowledge, as well as expert models and high-quality multimodal datasets accumulated on the COSMOMind Industrial Big Data. It possesses significant advantages in industrial scenario analysis, knowledge Q&A, and logical reasoning, with a retrieval accuracy rate of up to 93% in industrial knowledge fusion and retrieval. Through the "one industry, one model" strategy, COSMOPlat has developed industry-specific large models for enterprises in home appliances, energy and chemicals, energy and carbon industries, providing intelligent decision-making support for major industrial scenarios including research and development design, production manufacturing, operation services and dual-carbon management.Industry intelligent agents and industrial software serve as the “air link”, transforming the decision-making instructions of large models into more flexible human-machine interaction methods and more efficient execution capabilities. As of the Latest Practicable Date, COSMOPlat has developed 57 industrial intelligent agents covering over 40 core scenarios across 3 major industries, which can handle key industrial functions such as process optimization, equipment management, and smart energy and carbon, helping customers achieve intelligent control of industrial processes, shorten process parameter adjustment cycles, improve equipment operation and maintenance efficiency, and reduce production energy consumption and energy costs.At the “ground” level, intelligent terminals and automation equipment, acting as the executing limbs, transform AI capabilities into actual production actions and integrate them into the entire manufacturing process, achieving efficient synergy among data, equipment and scenarios, driving industrial AI from isolated intelligent applications to domain-wide intelligence, creating value-added throughout the entire process for customers across various industries, and maximizing the release of data value.Relying on the “space-air-ground integrated” full-stack AI technology system, COSMOPlat has achieved full-link intelligence across “perception-analysis-decision-execution-feedback”, forming a unique flywheel effect of “data accumulation—model refinement—intelligent agent deployment—data reinforcement”, achieving self-reinforcement and a virtuous cycle where “more data is generated through use, models become more precise through use, and intelligent agent scenarios become broader through use”, enabling COSMOPlat's AI capabilities to continuously evolve in practice and building a solid technology barrier.Practical Evidence: AI Empowerment from Concept to Significant Scenario Implementation ResultsThe value of technology must ultimately be tested by the market. COSMOPlat has demonstrated through numerous benchmark cases that its AI empowerment has moved beyond the “proof of concept” stage and is capable of delivering tangible economic benefits to enterprises.In the petrochemical industry, COSMOPlat has developed the world's first petrochemical large model covering the entire industry chain, entire ecosystem chain, and entire value chain, which has been implemented in a large-scale petrochemical enterprise. Based on the model, the Company has developed 38 intelligent agents, such as the dynamometer intelligent assistant and the aldehyde separation tower process optimization agent, covering scenarios such as oilfield extraction, oil and gas refining and chemical processing, and production safety, with an average efficiency increase of 20%. Taking the dynamometer intelligent assistant as an example, based on the professional capabilities of whole-network search and the COSMOMind, this intelligent agent can “read and understand” dynamometer data of industrial equipment such as deep well pumps, accurately identify equipment failures and provide disposal suggestions, improving the efficiency of oil well equipment failure diagnosis and disposal by more than 50%; the aldehyde separation tower process optimization assistant integrates historical data and expert knowledge, enabling dynamic identification and adjustment suggestions for key parameters, providing decision-making assistance for operators, and significantly enhancing quality control precision and the product first-time conversion rate; the intelligent oil blending assistant quickly generates optimal blending schemes through interpolation algorithms and non-linear programming models, balancing product performance with green production requirements, fully validating the practical value of AI in the heavy chemical industry.In core manufacturing scenarios, COSMOPlat integrates AI technology throughout the entire chain of R&D, production, operation and maintenance. On the R&D side, taking a home appliance interconnected factory selected as a world “lighthouse factory” as a typical example, an AIGC virtual design assistant was introduced. Based on massive user preference data and an expert design asset library, it generated core solutions for three-drum washing machines. By simulating inner drum operation scenarios in advance to construct a dynamic balance optimization model, it solved the industry pain point of “collisions and interference” during multi-drum operation at the source; on the production side, the injection molding industrial intelligent agent, through deep learning of injection molding professional knowledge, equipment operation data, and process data, etc., precipitated the debugging methods that previously existed only in the minds of process technicians into various intelligent algorithms, ultimately forming professional injection molding knowledge Q&A and automated process parameter recommendation capabilities, building the most powerful “industrial brain” in the field of injection molding.In the energy sector, COSMOPlat’s energy-carbon model (COSMOMind for energy-carbon) is the first energy-carbon model originating from sustainable lighthouse factory practices. Based on this model, COSMOPlat offers enterprises and industrial park users an Energy-Carbon Management Platform and end-to-end smart-energy solutions, helping customers lower energy cost, improve utilization and advance green manufacturing. These cross-industry and multi-scenario success stories strongly demonstrate the practical effectiveness and replicability of COSMOPlat’s AI solutions.From an industrial cycle perspective, as the manufacturing system grows increasingly complex and cost and efficiency constraints intensify, enterprises' demand for end-to-end digital and intelligent transformation will continue to rise, ensuring long-term certainty in industry development.COSMOPlat has pioneered the “space-air-ground integrated” technology system centered on large industrial models, with intelligent agents deeply embedded in production processes. This delivers a closed loop of perception, decision-making, and execution. Through multi-industry and multi-scenario validation, it demonstrates that AI possesses the capability to continuously generate industrial value. As application scenarios continue to expand, intelligent agents scale up, and the data flywheel effect intensifies, COSMOPlat is poised to translate its technological leadership into heightened platform stickiness and greater value per customer. Riding the wave of digital transformation, it is unlocking greater potential for value growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On February 6, Distinct Healthcare Holdings Limited ("Distinct Healthcare" or the "Company", Stock Code: 2677.HK), a leading player in China's mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company's scaled and high-quality development.On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company's growth potential. The active trading and high investor enthusiasm further corroborate the market's firm confidence in the consumer healthcare services sector and the Company's core value.Possessing a Large Customer Base with Continuously Improving ProfitabilityAs the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients' high recognition of Distinct Healthcare's service quality.Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth "without relying on medical insurance subsidies or excessive marketing expenditure". Financial data shows the Company's total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality DevelopmentDistinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare's core competitiveness, business model, and future development prospects, and will also provide powerful resource support and brand endorsement for the Company's subsequent development, helping it to further expand its industry influence.Regarding the use of IPO proceeds, Distinct Healthcare has formulated a clear strategic plan to ensure the proceeds are effectively deployed to support the Company's high-quality growth. Approximately 35% of the net proceeds will be allocated to digitalization and intelligent upgrades. By building a professional talent pool for medical AI applications, establishing strategic partnerships with leading research institutions and technology companies and making external procurements, while leveraging internal IT and data technology departments to iteratively optimize existing IT systems, the Company will deploy advanced AI technologies, optimize medical service workflows and enhance diagnostic efficiency as well as operational effectiveness.Approximately 30% of the net proceeds will be used for service network expansion and upgrades, primarily focusing on enhancing the diagnostic environment and equipment at existing medical service institutions. It will also advance the layout of new institutions, including relocating an existing institution in Shenzhen and establishing new institutions in key cities such as Hangzhou and Shanghai, thereby further expanding and improving service coverage in key domestic regions.Approximately 25% is earmarked for strategic mergers and acquisitions, acquire high-performing medical service institutions with strong synergies in first-tier and new first-tier cities when suitable opportunities arise, aiming to rapidly expand market share and strengthen regional competitiveness. The remaining approximately 10% will be used as working capital and for general corporate purposes, providing stable financial support for daily operations and business expansion.This clear strategic roadmap not only charts a clear course for the Company's future growth, effectively enhancing its core competitiveness and sustainability, but will also further reinforce its leading position in China's private mid-to-high-end healthcare sector. It will help propel the Company to new heights, achieving its long-term goals of scaled and high-quality development.This successful listing on HKEX represents a significant milestone in Distinct Healthcare's development journey, marking its official entry into a new phase driven by both "capital and industry". It will further elevate the Company's brand influence and financing capabilities, injecting powerful momentum for its future growth.Moving forward, Distinct Healthcare will remain true to its founding aspirations, staying focused on the mid-to-high-end healthcare services segment. It will continue to enhance medical service quality and patient experience, further unlock its growth potential and deliver sustainable long-term returns to its shareholders. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On 6 February, Muyuan Foods Co., Ltd. ("Muyuan Foods" or the "Company", Stock Code: 2714.HK), a global leader in the pork industry, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today, marking the beginning of a new chapter in the Company's international development.Powerful Cornerstone Investors Underscore Muyuan’s Industry LeadershipFor this Hong Kong IPO, Muyuan Foods successfully attracted a prestigious lineup of cornerstone investors, including Charoen Pokphand Foods, Wilmar International Limited (Wii Pte. Ltd. and HPRY), Sinochem Hong Kong, Hong Kong Henan AgriInternational, FIL Investment, RBC Global Asset Management (Asia) Limited and Ping An Life Insurance Company of China, Ltd., and other renowned institutions—14 in total—with combined subscription amounting to US$685 million. This formidable cornerstone investor group not only provides the Company with stable financial support but also brings abundant industrial resources and an international perspective, laying a solid foundation for its subsequent global expansion and valuation enhancement.As a technology-driven pork industry leader, Muyuan Foods has deep expertise cultivated over many years in the industry and has established a uniquely advantageous vertically integrated business model. Its operations comprehensively cover the entire pork industry chain, including hog breeding, hog farming, feed production, as well as slaughtering and meat production. Leveraging synergistic advantages across the entire chain, the Company has steadily maintained its leadership position in the hog farming industry.According to statistics from Frost & Sullivan, since 2021, measured by hog production capacity and hog sales volume, Muyuan Foods has become the world's largest hog farming enterprise. Its hog sales volume has ranked first globally for four consecutive years, solidifying its position as the industry leader. In terms of market share, the Company's global market share steadily increased from 2.6% in 2021 to 5.6% in 2024. As of 2024, this market share already exceeded the combined market share of the world's second to fourth largest participants in the hog farming industry, further widening the gap with peers and continuously highlighting its core competitiveness.Steady Earnings Growth Maintained; Active Overseas Market Expansion Strengthens CompetitivenessRelying on its full industry chain layout and efficient operational management, Muyuan Foods has maintained steady earnings growth in recent years, with profitability continuously improving, demonstrating the Company's operational resilience through solid business data. Data shows that the Company's revenue scale grew steadily from RMB124.826 billion in 2022 to RMB137.947 billion in 2024. Net profit surged significantly from RMB14.933 billion in 2022 to RMB18.925 billion in 2024, indicating remarkable growth and continuously optimized profitability. Entering 2025, the Company's growth momentum further accelerated. In the first nine months of 2025, the Company achieved operating revenue of RMB111.790 billion, a year-on-year increase of 15.5%, and realized a net profit of RMB15.112 billion, a substantial year-on-year increase of 34.4%. The double-digit growth in both revenue and net profit fully demonstrates the Company's strong development momentum and favorable profit outlook.While consolidating its leading position in the domestic market and achieving rapid self-development, Muyuan Foods has consistently anchored its global development strategy, actively expanding into overseas markets. Using the export of technology and equipment as a key approach, it empowers the upgrading of the global hog farming industry and builds an international farming ecosystem. In 2024, the Company entered into a deep strategic partnership with BAF Vietnam Agriculture, providing services including hog house design, biosecurity management, odor control solutions and smart hog farming to help its partner optimize farming efficiency, reduce operational costs, and practice environmentally responsible farming.The smooth progress of this cooperation marks a crucial first successful step for Muyuan Foods in its global layout, accumulating valuable experience for subsequent overseas market expansion. On the other hand, leveraging the vast potential of overseas markets, Muyuan Foods will further achieve optimized resource allocation and efficient synergy on a global scale, continuously broadening its corporate growth boundaries and diversifying profit sources, thereby solidifying its core advantages and enhancing comprehensive competitiveness.Overall, the successful listing in Hong Kong not only signifies that Muyuan Foods has formally entered a new stage of internationalized development, establishing an important bridge connecting global capital and resources, but also indicates that the Company's operational management level, industry competitiveness, and development potential have gained broad recognition from the international capital market. In the future, Muyuan Foods will seize this listing opportunity, adhere to the philosophy of technology-driven and green development, continue to deepen its involvement in the entire pork industry chain, constantly strengthen its core competitiveness, steadily advance its global layout, further consolidate its position as the global leader in the hog farming industry, and open up broader growth space. Its future development is worthy of market anticipation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 在中国资本市场,牧原股份(2714.HK)是一家伴随争议成长的公司:猪周期的波动、重资产投入、阶段性高负债的经营状态,曾多次成为市场热议的焦点。但拉长时间周期,这些曾被市场讨论的「争议点」,已经开始转化成为牧原股份难以复制的核心竞争壁垒。所谓的重资产投入,并非盲目扩张,而是精准布局生猪育种、饲料生产、养殖、屠宰肉食全产业链以及智慧养殖的必要投资,最终沉淀为行业领先的成本优势与抗周期能力。2月6日,这家深耕生猪产业三十余年的龙头企业,正式登陆香港联交所。此次上市不仅标志着牧原股份成功搭建了「A+H」双资本平台,获得了更广阔的国际融资渠道,更意味着公司向着「全球养殖巨头」的目标迈出了关键一步。行业变局下的领航者:重构生猪产业发展新范式生猪产业作为关乎民生的基础产业,长期以来受「猪周期」波动、疫病防控等痛点困扰。但近年来,随着环保政策趋严、规模化养殖提速、消费需求升级,行业正迎来结构性变革——产业集中度持续提升成为必然趋势。据行业数据显示,于2024年规模化生猪养殖的渗透率达到70.1%,且其预期将于2029年达到79.4%,但相较于美国2024年90%以上的集中度,仍有巨大提升空间。牧原股份率先突破传统养殖模式的局限,构建了覆盖生猪育种、生猪养殖、饲料生产、屠宰肉食的全产业链垂直一体化体系,实现了「从农场到餐桌」的全流程可控。这种模式不仅彻底解决了传统养殖「上下游脱节、成本高企、质量难控」的痛点,更形成了强大的协同效应——饲料环节为养殖环节提供低成本、高质量的饲料供应,养殖环节为屠宰环节提供稳定的生猪来源,屠宰环节则通过消费需求反哺育种与养殖环节,形成死循环发展。更为关键的是,牧原股份将科技深度融入产业全链条,从自主研发的空气过滤猪舍、智慧巡检机器人,到数据驱动的基因选育平台、优化豆粕日粮技术,牧原以技术创新持续优化养殖效率、降低成本、提升质量。截至2025年9月30日止九个月,公司平均PSY达到约28,领先行业平均水平;育肥猪日增重约841克,亦领先同业;年均完全成本进一步降至每公斤人民币12元,继续巩固其在养殖成本端的竞争壁垒。于往绩记录期间,牧原股份累计拥有专利超1700项,其降氨除臭解决方案、优化豆粕日粮技术更是被国家相关部门作为典型案例向全行业推广,引领生猪产业向智慧化、绿色化、标准化转型。价值投资的优选目标:稳健底色与长期回报兼具牧原的吸引力,不仅来自其强大的业务模式和技术优势,同样也源于其日益稳健的财务表现和清晰的股东回报政策。盈利端,尽管生猪行业具有明显的周期性特征,但牧原股份极致的成本控制能力,在过去十年中展现了超越周期的盈利能力。2014-2024年间,公司净利润复合年均增长率达到72.7%,平均年净利润率19.0%,是全球前十猪肉上市企业中唯一一家同期平均净利润率超15%的企业。即使在行业低谷期,公司仍能保持稳健盈利,展现出极强的盈利韧性。财务层面,随着前期大规模的产能建设逐步完成,牧原正进入「投资回报期」。2022-2024年累计经营活动现金流入净额已1.6倍覆盖累计资本性支出,2025年前三季度这一比例进一步提升至3.9倍。充裕的现金流不仅为公司继续扩大竞争优势提供了资金支持,也为持续分红和债务结构优化创造了条件。截至2025年三季度末,公司资产负债率为55.50%,负债总额较年初已下降约98亿元。此外,牧原股份始终重视股东回报,2022年至2025年前9个月累计派息166亿元。公司最新制定的2024-2026年股东回报规划,明确承诺每年以现金方式分配的利润由不少于当年实现的可供分配利润的40%。这一明确的回报政策,不仅体现了公司对股东的责任意识,也为其未来股价提供了重要的价值支撑。全球化布局启新程:从中国龙头到全球标杆此次港股上市,标志着牧原股份全球化战略进入新的发展阶段。在全球猪肉消费格局变化的背景下,公司正在从中国的龙头企业向世界级农业企业迈进。目前,牧原股份的海外布局已取得实质性突破,展现出强劲的落地能力。2024年与越南BAF农业有限公司达成战略合作,迈出海外拓展第一步;2025年8月,与正大集团签署战略合作协议,双方将围绕战略规划、业务整合与全球化布局等方面开展全方位合作,共同探索全球市场的巨大潜力;2025年9月,与BAF合作升级,双方合作在越南总投资32亿元的高科技楼房养殖项目,规划年出栏规模达160万头,展现了公司将国内成熟的养殖管理模式向海外复制的能力。按照牧原的战略规划,未来公司在通过技术服务、设备销售等轻资产模式进入海外市场的基础上,也会结合各地实际情况,选择多种方式开展国际化业务,包括在海外新建产能、开展有针对性的收并购等模式,海外业务的潜力增长将为公司带来对抗猪价风险的硬实力,提供新的增长空间。从行业发展趋势来看,长期稳态下,生猪养殖产业整体将保持合理的利润水平,而行业具备养殖管理和成本优势的企业望保持较好盈利能力。牧原股份养殖规模领先,养殖成本优势持续增强,盈利能力领先同行,此外,公司积极海外拓潜,向全球养殖巨头成长演化,展现出难得的确定性和成长性。随着公司在全产业链深耕、市场拓展方面的持续投入,其内在价值有望在未来几年得到进一步释放。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 当前,餐饮行业竞争日趋激烈,行业集中度逐步提升,消费者对食材新鲜度、口味标准化、品牌公信力的要求不断提高,具备核心供应链优势与清晰发展战略的企业愈发凸显竞争韧性。绿茶集团有限公司("绿茶"或"公司",股份代号: 6831.HK)作为休闲中式餐厅行业龙头,凭借优异、完善的供应链体系及前瞻性的国际化布局,成功突破行业发展瓶颈,化解传统餐饮运营痛点,在行业同质化竞争中脱颖而出。独特优秀供应链模式 助力菜品迭代升级提升核心竞争力优秀的供应链是餐饮企业的核心竞争力,是保障菜质量量、控制运营成本、实现规模化拓店的关键支撑,更是餐饮品牌穿越行业周期、实现长效发展的坚实根基。从供应链的演变方面来看,餐饮行业供应链经历了三次重要迭代:第一代供应链以"当地采购+厨房现炒"为核心模式,其劣势在于食材采购分散、难以实现标准化生产,且食材质量参差不齐、溯源体系不完善,无法支撑品牌规模化拓店;第二代供应链升级为"中央厨房+厨房加工"模式,虽在一定程度上解决了标准化问题,但受限于菜品加工模式,难以满足当下消费者对"现做现吃"的新鲜度需求,制约了品牌口碑提升。而绿茶精准把握行业痛点与消费趋势,创新采用第三代供应链模式:头部供应商+数字化冷链+智能厨房,该模式实现了"质量可控、新鲜现炒、口味标准"三者的有机统一,既规避了前两代供应链的核心短板,又兼顾了规模化运营与消费体验,成为行业供应链升级的标杆。在供应商合作层面,绿茶坚持与头部优质供应商深度绑定,构建稳定、高质量的食材供应体系,其供应商主要包括北京古船食品有限公司、正大集团、紫燕食品等行业龙头企业。其中,古船食品是集面粉加工、食品生产、产品研发、粮食储备、粮食贸易、销售服务为一体的大型国有企业,凭借严格的质量管控体系与稳定的产能,为绿茶提供高质量的面制品食材;正大集团成立于1921年,是知名跨国企业,在全球拥有完善的养殖、加工体系,为绿茶提供新鲜、安全的畜禽类食材,双方的深度合作为公司保障了食材质量。仓储物流方面,绿茶搭建了覆盖全国的数字化冷链仓储体系,目前在全国布局8大中心仓,广泛覆盖华南、华北、华东、西南等国内主要消费区域,食材由供应商直接运送至各中心仓后,通过精准分拣、动态管控,再以全程冷链运输的方式,配送到全国各大门店,全程实现食材溯源可查、温度实时监控,确保食材新鲜直达,从源头守住菜品质量底线。与这些头部供应商的深度合作,对绿茶的发展形成了双重赋能,一方面,头部供应商的严格质量管控体系与稳定的产能,让公司的食材供应更具保障,产品溯源体系更加完善,专业化程度持续提升,进一步强化了品牌口碑;另一方面,规模化的集中采购模式有效降低了食材采购成本,同时借助供应商的研发资源,助力绿茶实现菜品迭代升级,持续优化产品结构,提升核心竞争力。以绿茶爆款产品——绿茶烤鸡为例,其全流程运营充分彰显了第三代供应链模式的优势。绿茶先根据市场需求与产品标准,向供应商下达定制化采购订单,明确指定鸡的品种、养殖标准及规格要求;供应商按照订单要求进行标准化订单化养殖,确保鸡的生长环境与质量达标;在满足出栏条件后,利用全自动化生产线完成屠宰、消毒、分拣、清洗等一系列加工流程,严格控制每只鸡的规格,确保产品标准化;全程采用0-4℃冷链运输,送达绿茶对应区域中心仓;中心仓收到食材后,根据各门店订单需求进行快速分拣并发往各大门店;门店收到食材后,严格按照公司制定的SOP标准进行腌制,确保口味统一,当顾客下单后,门店员工将腌制好的冰鲜烤鸡放入定制化智能烤箱,烤箱预设定制化专属烤鸡模式,根据烤箱提示完成操作即可出餐。整个流程既保障了烤鸡的新鲜度与口味标准化,又提升了出餐效率,实现了"标准化生产"与"现做现吃"的完美平衡,成为绿茶深受消费者喜爱的核心原因之一。积极布局国际化市场 商业价值与盈利潜力不断提升在深耕本土市场、持续完善供应链体系的同时,绿茶积极布局国际化市场,开启"本土深耕+海外布局"的双轮驱动发展模式,逐步实现品牌的全球化布局。绿茶的出海布局并非偶然,而是具备深厚的基因与坚实的支撑,一方面,公司创始人王董在从事餐饮服务行业之前,拥有丰富的海外经商经验,深刻洞察到海外中餐市场的巨大潜力,出海基因深深烙印在品牌发展之中;另一方面,公司的战略投资者合众集团是一家总部位于瑞士的全球顶级私募投资管理公司,拥有深厚的全球化资源与海外市场运营经验,其全球化的海外背景为绿茶出海提供了强大的资源支持与专业指导,助力绿茶快速适应海外市场环境,降低出海风险。相较于其他中餐品牌,绿茶出海具备多方面独特优势,在菜品方面,绿茶以"中西融合"为核心定位,打造适配全球消费者口味的融合菜,使其菜品具备广泛的市场适应能力,多款核心菜品已深受海外消费者的喜爱;同时,绿茶拥有经验丰富的菜品研发团队,能够快速筛选、优化适配当地市场的菜品,加快品牌融入当地市场的速度。在门店环境与品牌文化层面,绿茶始终坚持将中国传统文化与江南水乡风格融入门店装修设计,打造兼具东方美学与舒适体验的用餐环境。随着中国文化自信的提升与海外市场对中国传统文化兴趣的持续升温,绿茶独特的装修风格与品牌形象,不仅吸引了大量消费者到店用餐,更收获了广泛的品牌关注,成为中国文化出海的重要载体之一。在运营管理方面,目前海外中餐市场缺乏成规模、标准化的大型连锁品牌,而绿茶作为国内休闲中餐赛道的头部连锁品牌,经过多年的发展,积累了丰富的运营经验,形成了完善的运营管理体系。这种成熟的运营管理能力,是海外中小型中餐品牌无法比拟的核心优势,为公司海外门店的快速复制与稳定运营提供了有力保障。作为绿茶国际化布局的起点,公司于2024年9月在中国香港开设首店后,开启国际化拓店的序幕;截至目前,绿茶已在中国香港及海外市场开设门店共计15家,覆盖中国香港、新加坡、马来西亚、泰国等国家和地区,初步完成了中国香港及东南亚市场的布局,品牌海外影响力逐步提升。值得注意的是,公司境外门店的盈利水平显著高于国内门店,其收入和利润规模往往是国内门店的2.5-3倍左右。以中国香港门店为例,其月均收入稳定在150万-200万的较高水平,门店层面经营利润率约为15%以上,充分体现了绿茶境外布局的商业价值与盈利潜力。未来,绿茶的国际化扩张步伐将持续加快,2026年至少新增开设15家海外门店,主要分布在马来西亚、越南等核心潜力市场国家,预计到2026年底,港澳台及海外门店总数将突破30家,实现规模化布局;同时,2026年的利润将有望占集团新增利润的20%,成为公司核心利润增长点之一,进一步推动公司整体业绩提升。总体而言,绿茶凭借行业领先的供应链体系,深厚的出海基因与独特的竞争优势,积极布局国际市场,打开了全新的成长空间。未来,在供应链持续赋能与国际化布局不断深化的双重优势加持下,公司将持续巩固行业龙头地位,实现本土市场与海外市场的协同发展,具备广阔的成长潜力与发展前景,有望成为引领中式餐饮全球化发展的标杆品牌。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective,VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
All-new Versa VanTOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Mitsubishi Motors Philippines Corporation (MMPC), a subsidiary of Mitsubishi Motors in the Philippines, began sales of the all-new Versa Van on February 6. The model is an OEM-supplied commercial vehicle by Nissan Motor Co., Ltd. (hereafter, Nissan).The all-new Versa Van offers five-row seating for up to 15 passengers and features a spacious interior optimized for transporting people, supporting a wide range of commercial applications, including shuttle services. Powered by a 2.5-liter inline four-cylinder diesel engine, the model delivers strong torque from the moment of acceleration, ensuring confident performance even when carrying many passengers or driving on steep inclines. With this new model, Mitsubishi Motors aims to strengthen its commercial vehicle lineup in the Philippines and meet customer needs alongside the existing L300 model.As Alliance partners, Mitsubishi Motors and Nissan are pursuing global collaboration in areas such as joint development and production of next-generation pickup trucks, as well as joining forces to drive business expansion in electrified vehicles. The OEM supply of the all-new Versa Van by Nissan for the Philippine market represents a tangible outcome of this collaboration. Mitsubishi Motors has also begun supplying Nissan with the Rogue Plug-in Hybrid for North America and the Navara for Oceania and has been supplying the Livina to the Philippine market since 2022 — an initiative that improves plant utilization and complements model lineups, building a mutually beneficial partnership. Furthermore, Mitsubishi Motors will receive OEM supply of an all-new EV model derived from Nissan’s new LEAF in 2026 and will introduce the model to the North American market in the latter half of the year.Mitsubishi Motors will continue to leverage diverse partnerships to expand its product lineup, strengthen regional operations, and accelerate initiatives that enhance profitability.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com